[1]KRIS MG,GASPAR LE,CHAFT JE,et al.Adjuvant systemic therapy and adjuvant radiation therapy for stage Ⅰ to Ⅲa completely resected non-small-cell lung cancers:American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2017,35(25):JCO2017724401.
[2]MASTERS GA,SAEAH T,AZZOLI CG,et al.Systemic therapy for stage Ⅳ non-small-cell lung cancer:American Society of Clinical Oncology Clinical Practice Guideline Update[J].J Oncol Pract,2017,33(30):832-837.
[3]于舒飞,王燕.EGFR野生型肺腺癌的治疗策略[J].癌症进展,2012,10(6):605-611.
YU SF,WANG Y.Treatment strategy of EGFR wild-type lung adenocarcinoma[J].Cancer Progress,2012,10(6):605-611.
[4]毕金玲,刘海源,黄勇.阿帕替尼单药治疗进展期非小细胞肺癌疗效观察[J].临床肺科杂志,2017,22(8):1474-1476.
BI JL,LIU HY,HUANG Y.Observation of the efficacy of apatinib monotherapy in advanced non-small cell lung cancer[J].Journal of Clinical Pulmonary Medicine,2017,22(8):1474-1476.
[5]冯久桓,秦叔逵,王琳.甲磺酸阿帕替尼的研究现状与进展[J].临床肿瘤学杂志,2017,22(4):345-356.
FENG JH,QIN SK,WANG L.Research status and progress of apatinib mesylate[J].Journal of Clinical Oncology,2017,22(4):345-356.
[6]BESSE B,ADJEI A,BAAS P,et al.2nd ESMO consensus conference on lung cancer:non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease[J].Annals of Oncology,2014,25(8):1475-1484.
[7]DING L,LI QJ,YOU KY,et al.The use of apatinib in treating non small-cell lung cancer:Case report and review of literature[J].Medicine,2016,95(20):e3598.
[8]LANGER CJ,MOK T,POSTMUS PE.Targeted agents in the third-/fourth-line treatment of patients with advanced(stage Ⅲ/Ⅳ) non-small cell lung cancer(NSCLC)[J].Cancer Treatment Reviews,2013,39(3):252-260.
[9]PENG S,ZHANG Y,PENG H,et al.Intracellular autocrine VEGF signaling promotes EBDC cell proliferation,which can be inhibited by Apatinib[J].Cancer Letters,2016,373(2):193-202.
[10]刘仁旺,刘京豪,李昕,等.EGFR 19和21外显子突变肺癌患者的临床特征比较和预后分析[J].中国肺癌杂志,2014,17(011):804-811.
LIU RW,LIU JH,LI XIN,et al.Clinical characteristics and outcomes of lung cancer patients with EGFR mutations in exons 19 and 21[J].Chin J Lung Cancer,2014, 17(011):804-811.
[11]LIN Y,ZHAI ET,LIAO B,et al.Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer［J］.Oncotarget,2017,8(7):11990-12002.
[12]LIN C,WANG S,XIE W,et al.Apatinib inhibits cellular invasion and migration by fusion kinase KIF5B-RET via suppressing RET/Src signaling pathway[J].Oncotarget,2016,7(37):59236-59244.
[13]GOMAA A,WAKED I.Management of advanced hepatocellular carcinoma:review of current and potential therapies[J].Hepatoma Research,2017，3(1):112-122.
[14]LI J,QIN S,XU J,et al.Randomized,double-blind,placebo-controlled phase Ⅲ trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction[J].Journal of Clinical Oncology,2016,34(13):1448-1454.
[15]ROVIELLO G,POLOM K,ROVIELLO F,et al.Targeting VEGFR-2 in metastatic gastric cancer:Results from a literature-based meta-analysis[J].Cancer Investigation,2017,35(3):187-194.
[16]TER VEER E,HAJ MOHAMMAD N,VAN VALKENHOEF G,et al.Second-and third-line systemic therapy in patients with advanced esophagogastric cancer:a systematic review of the literature[J].Cancer and Metastasis Reviews,2016,35(3):439-456.
[17]ILSON DH,HILLEGERSBERG R.Management of patients with adenocarcinoma or squamous cancer of the esophagus[J].Gastroenterology,2018,154(2)437-451.
[18]SCOTT AJ,MESSERSMITH WA,JIMENO A.Apatinib:a promising oral antiangiogenic agent in the treatment of multiple solid tumors[J].Drugs of Today,2015,51(4):223.
[19]HU X,ZHANG J,XU B,et al.Multicenter phase Ⅱ study of apatinib,a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple negative breast cancer[J].International Journal of Cancer,2014,135(8):1961-1969.
[20]PAZ-ARES L,HIRSH V,ZHANG L,et al.Monotherapy administration of sorafenib in patients with non-small cell lung cancer(MISSION) trial:A phase Ⅲ,multicenter,placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung cancer after 2 or 3 previous treatment regimens[J].J Thorac Oncol,2015,10(12):1745-1753.
[21]ZENG DX,WANG CG,LEI W,et al.Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma[J].Oncotarget,2017,8(39):66248-66253.
[22]FANG SC,ZHANG HT,ZHANG YM,et al.Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma[J].OncoTargets and Therapy,2017,10:447-452.
[23]ZENG DX,WANG CG,HUANG JA,et al.Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation[J].OncoTargets and Therapy,2017,10:4269-4272.
[24]LI J,QIN S,XU J,et al.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:Results from a randomized,placebo-controlled,parallel-arm,phase Ⅲ trial[J].Journal of Clinical Oncology,2013,31(26):3219-3225.